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1. Introduction 
Aurbach and colleagues [ 1,2] have recently devel- 
oped an iodinated adrenergic antagonist [ 12’1] iodo- 
hydroxybenzylpindolol [i2’IHYP) of very high specific 
activity which binds in a sterospecific manner to 
fl-adrenergic receptors of partially purified membranes 
from turkey erythrocytes. The binding of 12’IHYP to 
membranes from rat heart [3], brain [4], human 
astrocytoma cells [5] and rat glioma cells [6] has also 
been reported. We have developed an in vivo assay for 
the binding of 12sIHYP to intact glioma cells. This 
method has many advantages over the in vitro assay 
and would allow the identification and direct localiza- 
tion of P-receptor on cells in tissue culture and tissue 
sections by autoradiography. 
2. Materials and methods 
2.1. Growth of C6 rat glioma cells and binding of 
iodohydroxybenzylpindolol 
HYP (generously donated by Dr Hauser, Sandoz) 
was iodinated with “‘1 as described by Maguire et al. 
[6]. Its specific activity was 600 Ci/mmol. C6 Bat 
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glioma cells were grown on Falcon tissue culture 
plates in DMEM (Gibco) supplemented with 10% fetal 
calf serum (Gibco), under an atmosphere of 95% 
air, 5% C02. The cells in exponential-phase of growth 
were detached by trypsinization, distributed into 
3.5 cm plastic Petri dishes and allowed to recover for 
48 h in fresh medium before the binding assay. Each 
dish was washed twice with 5 ml PBS and incubated 
for 30 min. at 37°C with 0.8 ml PBS (or serum, as 
indicated) containing 0.34 nM lXIHYP (144 000 cpm), 
supplemented or not with 5 - lo-’ M phentolamine. 
After incubation the medium was aspirated and the 
plates washed five times with 2 ml PBS at room 
temperature, followed by six more washings with 
2 ml PBS, for 10 min periods. In the standard assay, 
PBS used for washing, was also supplemented with 
5 . lo-’ M phentolamine. Propranolol was present, 
as indicated, during the incubation of the cells with 
12’IHYP. The ceils were routinely detached from the 
plates, after washing with 1 ml 0.1% trypsin in D-l 
isotonic buffer and counted in a gamma-counter. 
Detaching the cells from the dishes by scraping with a 
rubber policeman or by using trypsin 0.1% in D-l 
isotonic buffer gives equal bindings properties (data 
not shown). 
3. Results 
In preliminary experiments ‘specific’ binding was 
defined as the percentage of 12sIHYP displaced when 
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20 PM (k) propranolol was included in the binding 
step. Only 20-30% ‘specific’ binding could be achieved 
when the plates were washed five times. Inclusion of 
10% fetal calf serum or serum albumin (10 mg/ml) 
did not improve the efficiency of the washing proce- 
dure. The percentage of rz51HYP specifically bound 
could be increased to 90% by further washing the 
plates 6 times, for 6 X 10 min periods, with PBS at 
room temperature. 1251HYP non-specifically bound 
decreased linearly during these washing periods while 
the amount specifically bound remained constant. 
Brown et al. [2] and Maguire et al. [6] have observed 
dissociation of bound 12’IHYP only in the presence 
of competing cold HYP [2] or propranolol [6]. 
Prolonged washing is probably rendered necessary 
by the very high proportion of the 12’IHYP non- 
specifically bound to the membrane (70% of the load). 
Saturation of the binding sites could, however, not 
be observed under these conditions. As shown in fig. 1, 
inhibition of binding by (-) propranolol is biphasic. 
Only inhibition at low concentrations (up to 10e7 M) 
of propranolol reflects binding to adrenergic receptors. 
At higher concentrations, the inhibition is not stereo- 
specific and affects non specific sites. Similar observa- 
tions have been made in vitro in the C6 glioma cell- 
line [6] and in rat brain [4]. Specific binding was 
thus redefined as the decrease in bound 1251HYP 
observed when the cells were coincubated with 
0.1 PM (+-) propranolol. As shown in fig.2 a saturable 
binding curve was obtained in this way. 
In order to decrease the percentage of 1251HYP 
bound non-specifically, two approaches were under- 
taken. Cells were incubated with 12’IHYP in PBS 
containing varying concentrations of fetal calf serum. 
There is a proportional decrease of the binding to 
non-specific sites with increasing concentrations of 
serum. Therefore it is reasonable to consider a parti- 
tion of the non-specifically bound 1251HYP between 
the membranes and serum components compare 
with the partition of cholesterol between plasma high 
density lipoprotein [14,15] and arterial smooth-muscle 
Fig.2. Saturation of ‘251HYP-binding in PBS. 3.1 . lo6 Cells 
(1 mg protein) were incubated with various concentrations 
of “‘IHYP 
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cells). Furthermore the high hydrophobicity of HYP 
favors its solubility in the lipid-phase of the membrane. 
It must be noted that different types of cells bind 
‘*‘IHYP non-specifically to a different extent. This 
may be related to the fluidity of their membrane. 
Brown et al. have recently reported [ 131 and we have 
independently observed (data not shown) that a much 
smaller percentage of 1251HYP is non-specifically bound 
to intact erythrocytes compared to C6 glioma cells. 
We have also observed (results unpublished) that at 
stationary phase, the extent of non-specifically bound 
‘*‘IHYP increases. As shown in fig.1 the displacement 
curve of ‘*‘IHYP in the presence of (-) propranolol, 
with the cells loaded in the presence of 100% fetal 
calf serum is no longer biphasic, indicating the sup- 
pression of the high percentage of binding to non- 
specific sites. However a clear saturation of specific 
“‘IHYP binding sites could not be achieved by loading 
the cells in 100% fetal calf-serum. 
Therefore a standard assay was developed based on 
the report by Sporn and Molinoff [4] that phentol- 
amine could markedly reduce non-specific binding to 
membranes from cerebral cortex, caudate nucleus and 
cerebellum. Phentolamine at concentrations of 
0.1-0.05 mM eliminated the in vivo binding of 
‘*‘IHYP to non-specific sites in C6 glioma cells, as 
shown in fig.1 and fig.3. In the presence of phentol- 
amine, (-) propranolol was a more potent inhibitor of 
the ‘*‘IHYP binding, by 2 orders of magnitude, than 
0.5 1.0 1.5 
[‘*51 HYPI n M 
the corresponding (t) isomer. The K, of 1251HYP 
determined by Scatchard analysis of the data of fig.3 
was 1.4 . lo-” M which compares to similar values 
obtained in vitro [6] . From fig.3 it was calculated 
that there were 7000 /3-adrenergic receptors/C6 
glioma cell. This value was very reproducible and did 
not vary with the phase of growth of the cells (results 
not shown). The enhanced sensitivity of glioma or 
astrocytoma cells to catecholamines in the stationary- 
phase of growth [7] is not caused by an increase in 
the number of /I-adrenergic receptors. Our value of 
7000 receptors/cell is higher than the-number obtained 
in vitro (4000) [6], probably due to partial loss or 
damage of the plasma membranes during their prepa- 
ration. It can be concluded from these results that 
the properties of the in vivo binding of 1251HYP are 
qualitatively similar to those obtained in vitro in a 
membrane preparation. However, the in vivo assay 
is more physiological and should allow the determina- 
tion of the spatial distribution of the &receptors by 
autoradiography. 
Incubation of the C6 cells with the P-agonist, iso- 
proterenol was associated with a net loss of receptors, 
as shown in fig.4, 50% of the 12sIHYP binding capa- 
city of the intact cells was lost after 2 h of exposure 
to isoproterenol. This observation suggests that the 
disappearance or inactivation of the /3-adrenergic 
receptors could be one of the mechanisms responsible 
for the desensitization phenomenon described earlier 
Hours of exposure to isopmtemnol 
Fig.3. Saturation of l”sIHYP-binding in PBS + phentolamine. 
3.1 . lo6 Cells were incubated with ‘2”IHYP in PBS + 
5 . lo-’ M. (n.0) or low4 M (e,o) phentolamine and washed 
as indicated in fig.1. (-e-e-) rZSIHYP Specifically bound, 
displaced by 0.1 nM DL-propranolol. (-o-o-_) “‘IHYP 
Non-specifically bound. 
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Fig.4. Loss of ‘2sIHYP-receptors after incubation with iso- 
proterenol. Cells were incubated with low4 M DL-isoproterenol 
in DMEM supplemented with 10% serum, at 37”C, for various 
periods. p-Adrenergic receptors were then quantified as 
described in fig.3. 
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in the C6 cell-line [8-l l] . A similar observation has 
been made in frog erythrocytes [ 121. Partial reversal 
of catecholamine refractoriness has also been obtained 
by inhibitors of RNA and protein synthesis acting at 
the level of phosphodiesterase [8] or elsewhere 
[8,10,11]. These results, taken together, indicate that 
desensitization to catecholamines may be due to at 
least two independent mechanisms. However, there 
is no clear relationship between desensitization and 
morphological changes. Serum removal, which 
increases cyclic AMP levels [7] and induces a marked 
change in the morphology of the cells does not affect 
their number of /3-adrenergic receptors. 
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